- Home
- CNTX vs ENTX Comparison
CNTX vs ENTX Comparison
Compare CNTX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- ENTX
- Stock Information
- Founded
- CNTX 2015
- ENTX 2010
- Country
- CNTX United States
- ENTX Israel
- Employees
- CNTX N/A
- ENTX N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTX Health Care
- ENTX Health Care
- Exchange
- CNTX Nasdaq
- ENTX Nasdaq
- Market Cap
- CNTX 75.6M
- ENTX 82.2M
- IPO Year
- CNTX 2021
- ENTX 2018
- Fundamental
- Price
- CNTX $1.13
- ENTX $1.91
- Analyst Decision
- CNTX Strong Buy
- ENTX Strong Buy
- Analyst Count
- CNTX 7
- ENTX 1
- Target Price
- CNTX $5.20
- ENTX $10.00
- AVG Volume (30 Days)
- CNTX 260.4K
- ENTX 50.8K
- Earning Date
- CNTX 11-05-2025
- ENTX 11-07-2025
- Dividend Yield
- CNTX N/A
- ENTX N/A
- EPS Growth
- CNTX N/A
- ENTX N/A
- EPS
- CNTX N/A
- ENTX N/A
- Revenue
- CNTX N/A
- ENTX $166,000.00
- Revenue This Year
- CNTX N/A
- ENTX N/A
- Revenue Next Year
- CNTX N/A
- ENTX N/A
- P/E Ratio
- CNTX N/A
- ENTX N/A
- Revenue Growth
- CNTX N/A
- ENTX 191.23
- 52 Week Low
- CNTX $0.49
- ENTX $1.50
- 52 Week High
- CNTX $2.59
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- CNTX 69.12
- ENTX 53.16
- Support Level
- CNTX $0.98
- ENTX $1.84
- Resistance Level
- CNTX $1.29
- ENTX $1.93
- Average True Range (ATR)
- CNTX 0.09
- ENTX 0.08
- MACD
- CNTX 0.02
- ENTX 0.01
- Stochastic Oscillator
- CNTX 65.91
- ENTX 68.18
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.